Metabolic Syndrome: Current State and Prospects

Metabolic syndrome (MetS), first conceptualized in 1923, encompasses a cluster of metabolic abnormalities, including insulin resistance (IR), hyperglycemia, dyslipidemia, hypertension, and central obesity. This syndrome significantly increases the risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Its global prevalence has surged, largely attributed to lifestyle factors such as poor diet and physical inactivity. Recent research highlights the crucial role of caveolae, small cellular structures, in the pathophysiology of MetS, particularly in insulin signaling, lipid metabolism, and vascular function. Managing MetS effectively requires a comprehensive strategy focused on lifestyle modifications and pharmacological treatments. Dietary approaches, environmental factors, regular physical activity and behavioral changes have demonstrated positive impacts on metabolic health. Despite current pharmacological options to individual conditions of MetS, emerging therapies targeting caveolae offer promising new avenues for treatment. While, microbiome modulation and certain natural agents may assist in managing the syndrome. Public health initiatives, including educational campaigns and stress reduction programs, are essential for the prevention and management of MetS. A multifaceted approach combining lifestyle changes, pharmacotherapy, and personalized interventions is vital for effective management. Future strategies may benefit from precision medicine and the integration of emerging biomarkers for targeted therapies.